参考文献
[1]王振义,李家增,阮长耿,等.血栓与止血基础理论与临床[M].3版.上海:上海科学技术出版社, 2004:300-399.
[2]林果为,欧阳仁荣,陈珊珊,等.现代临床血液病学[M].上海:复旦大学出版社,2013:1460-1482.
[3]黄绍良,陈纯,周敦华.实用小儿血液病学[M].北京:人民卫生出版社,2014:434-455.
[4]张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2008:19-23,191-195.
[5]蒋与刚,高志贤.营养基因组学[M].北京:科学出版社,2012:294-309.
[6]杨宝峰.基础与临床药理学[M].2版.北京:人民卫生出版社,2014:252-263.
[7]陈吉生.新编临床药物学[M].北京:中国中医药出版社,2013:547-555.
[8]沈丕安.中药药理与临床运用[M].北京:人民卫生出版社,2006:75-998.
[9]中化医学会血液学分会血栓与止血学组,中国血友病协作组.血友病诊断与治疗中国专家共识(2013年版)[J].中华血液学杂志,2013,34(5):461-463.
[10]真木正博.止血の実際[M].东京:金原出版株式会社,1970:1-200.
[11]刘陕西.止血剂的合理应用[M].西安:陕西科学技术出版社,1986:2-98.
[12]刘陕西.出血性疾病:内科学表解[M].西安:陕西科学技术出版社,1987:111-118.
[13]郑士敏.骨科必读[M].北京:人民卫生出版社,2014:294-299.
[14]T Duckworth,C M Blundell.临床笔记:骨科学[M].刘培来,李德强,张元凯,译.济南:山东科学技术出版社,2014:74-80.
[15]宁志杰,孙磊,吴复元.现代骨科临床检查诊断学[M].北京:人民军医出版社,2007:2-9.
[16]阮长耿.现代血液病诊断治疗学[M].合肥:安徽科学技术出版社,2007:156-162.
[17]柴田昭,三浦亮.ESSENTIALS OF HEMATOLOGY [M].日本医药出版株式会社,1987.
[18]高怡瑾.血友病的诊断治疗研究进展[J].国际儿科学杂志,1999(4):169-171.
[19]董炘.人体解剖学[M].2版.北京:人民卫生出版社,2015:125-126.
[20]李梅,高占成.重视呼吸系统罕见病诊断[J].内科理论与实践,2016(4):197-201.
[21]胡品津,谢灿茂.内科疾病鉴别诊断学[M].6版.北京:人民卫生出版社,2014:695-701.
[22]杨仁池,王鸿利.血友病[M].上海:上海科学技术出版社,2007:195-213.
[23]丁培芳,张志传,张心声,等.血友病A患者抗-HCV和抗-HIV阳性率调查分析[J].中国输血杂志,2002:212-213.
[24]国家药典委员会.中华人民共和国药典[M].北京:医药科技出版社,2010.
[25]干国平,刘焱文,李秋怡.川芎的化学成分及药理研究进展 [J].时珍国医国药,2006,17(7):1298-1299.
[26]康军.当归化学成分及其药理作用研究进展[J].中医中药,2005,2(23):120.
[27]柳永青.当归的化学成分与生物活性[J].航空航天医药,2009,20(11):127-128.
[28]叶仕高.内科学[M].6版.北京:人民卫生出版社,2004:663-666..
[29]刘巍等.蜜炙黄芪的化学成分研究[J].中国药物化学杂志,2008,04(18):142-146.
[30]陈慧珍.当归的研究进展[J].海峡药学,2008,20(8):83-85.
[31]杨立娟.川芎的药理作用研究进展[J].黑龙江医药,2010,23(4):599-600.
[32]李宏霞,韦升坚.地黄化学成分与药理药化研究[J].中国中医药现代远程教育,2012,10(17):116-117.
[33]王海峰.海马的现代研究进展[J].社区医学杂志,2011,9(12):44-45.
[34]刘荣华,邵峰,邓雅琼,等.山楂化学成分研究进展[J].中药材,2008,31(7):1100-1102.
[35]刘家兰,徐晓玉.山楂的药理作用研究进展[J].中草药,2009,40(增刊):63-65.
[36]夏红旻,孙立立,孙敬勇,等.地榆化学成分及药理活性研究进展[J].食品与药品,2009,11(7):67-69.
[37]符影,程悦,陈建萍,等.鸡血藤化学成分及药理作用研究进展[J].中草药,2011,42(6):1229-1234.
[38]邱蓉丽,李璘.中药女贞子化学与药理研究进展[J].中药材,2007,30(7):891-893.
[39]李建平,王静,张跃文,等.菟丝子的研究进展[J].中国医药导报,2009,6(23):5-6
[40]冯晶.淫羊藿的研究进展[J].湖北中医杂志,2012,34(9):74-75.
[41]高雪岩,王文全, 魏胜利,等.甘草及其活性成分的药理活性研究进展[ J].中国中药杂志,2009,34(21):2695-2700.
[42]Yong Ren-Chi.Comments on Chinese experts consensus on the diagnosis and treatment of acguired hemophilia A[J].J Cin Hematol(China)2004,27(7):547-549.
[43]Franchini M, Lippi G, Favaloro E J.Acquired inhibitors of coagulation factors:part 11 [J].Scnin Throml,Hemosi, 2012, 38:447-453.
[44]Coppoi A A, Favaloro E J, Tufano A.et al.Acquired inhibitors of coagulation factors:part I-acquired hemophilia A [J].Semin Thromb Hemost, 2012, 38:433-446.
[45]Knoebi P, Marco P, Baudo F, et al.Demographic and clinical data in acquired hemophilia A: results form the European acquired Haemophilia Registry(EACH2)[J].J Thromb Homeost, 2012,10:622-631.
[46]Collins P, Baudo F, Knoebl P.et al.Immunosuppression for acquired haemophilia A:results from the European Acquired Haemophilia Reqistry (EACH2) [J].Blood, 2012, 120:47-55.
[47]Baudo F, Conllins P, Huth-Kuhne A, et al.Management of bleeding in acquired hemophilia A:results from the European Acquired Haemophilia(EACH2)Registry[J].Blood, 2012, 120:16-39.
[48]Tengborn L, Baudo F, Huth-Kuhne A, et al.Pregnancy-associated acquired haemophilia A.results from the European Acquired Haemophilia (EACH2) registry[J].Bjog, 2012, 119:1529-1537.
[49]Huth-Kuhne A, Baudo F, Collins P.et al.International recommendations on the diagnosis and treatment of patients with acquired hemophilia A [J].Haematologica,2009, 94:566-575.
[50]Gupta S,Siddiqi A E,Soucie J M,et al.The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with maemophilia[J].Br J Haematol,2013, 161:424-433.
[51]Srivastava A,Brewer A K,Mauser-bunschoten E P,et al.Guidelines for the management of hemophilia.haemophilia[J],2013,19-47.
[52]Tong W,Wang J Z.Comparison of Efficacy and safety of tamsulosin Versus Nifedipine and Racanisodamine in the Treatment of Lower Ureteral Calculi[J].China Pharmacy,2016, 27(21):2915-2917.
[53]Li L L,Jiang W,Wang S Y.Clincal observation of Progesterone in teatmeng of urolithiasis[J].Chinese and Foreign Medical Research,2011,9(26):23-24.
[54]Pettersson H,Ahberg A, Nilsson M,et al.Amdiological classification of hemophilic arthropathy[J].Clin Orthop,1980, 149(6):153-159.
[55]杨秀伟.红参化学、药理和临床研究进展[J].中成药研究,1984,(5):30-33.
[56]Zappa S, Mcdaniel M, Marandola J,et al.Treatment trends for Hemophilia A and haemophilia B in the United States: results from 2012 Practice pattems Survey[J].Haemophilia,2012, 18(3):e140-153.
[57]Kasper C K.Concentrate Safety and efficacy[J].Haemophilia Practice, 2012,8(3):161-165.
[58]Ghosh K, Nair A P,Juina F,et al.Intracranial haemorrhage in severe haemophilia:prevalense and outcome in a developing country[J].Haemophilia, 2005,11(5):459-462.
[59]Mulder K,Llinás A.The target joint[J].Haemophilia, 2004,10:152-156.
[60]Su Y,Wong W Y,Lail A,et al.Long-term major joint outcomes in young adults with haemophilia: interim data from the HGDS[J].Haemophilia, 2007,3(4): 387-390.
[61]Yang R C,Wang H L.Haemophilia[M].Shanghai:Shanghai Science and Technology Press, 2007:36-39.
[62]Srivastava A,Brewer A K,Mauser-Bunschoten E P,et al.Guidelines for the management of hemophilia[J].Haemophilia, 2013,19(1):e1-e47.
[63]Knoebl P,Marco P,Baudo F,et al.Demographic and clinical data in acquired haemophilia A: results from the European Acquired Hemophilia Registry(EACH2)[J].J Thromb Hemost, 2012,10(4):622-631.
[64]Collins P,Baudo F,Knoebl P,et al.Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry(EACH2)[J].Blood,2012,120(1):47-55.
[65]Baudo F,Collins P,Huth-kühne A,et al.Management of bleeding in acquired hemophilia A: results from the European Acquired haemophilia(EACH2) Registry[J].Blood, 2012, 120(1):39-46.(https://www.daowen.com)
[66]V S Blanchette,N S Key.Difinitions in hemophilia: Communication From the SSC of the ISTH[J].Journal of Thrombosis and Hemostasis, 2014,12(11):1935-1939.
[67]De Palma A F,Cotler J M.Hemophilic arthropathy[J].AMA Arch Surg, 1956,72:247-250.
[68]Roosendal G,Vianen M E,Marx J J, et al.Blood-induced joint damage-ahuman in vitro study[J].Arthritis Rheum, 1999,42(5):1025-1032.
[69]Dürr H R,Stbler A,Maier M,et al.Pigmented villonodular Synovitis, Review of 20 cases[J].J Rheumatol, 2001,28(7):1620-1630.
[70]Li G Q,Zhang Y,Liu D,et al.P13 Kinase/Akt/HIF-1α Pathway is associated with Hypoxia-induced epithelial-mesenchymal transition in fibroblast-like synoviocytes of rheumatoid arthritis[J].Mol Cell Biochem, 2013,372(1):221-231.
[71]Rauner M,Stein N, Winzer M,et al.WNTSA in induced by inflammtory mediators in bone marrow stromal Cells and regulates cytokine and chemokine Production[J].J Bone Miner Res, 2012,27(3):575-585.
[72]Xiao C Y,Pan Y F, Guo X H,et al.Expression of β-catenin in rheumatoid arthritis fibroblast-like synoviocytes[J].Scand J Rheumatol, 2011,40(1):26-33.
[73]Harris S J,Foster J G,Ward S G.P13K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies[J].Curr Opin Investig Drugs, 2009,10(11):1151-1162.
[74]Grcevic D,Jajic Z,Kovacic N,et al.Peripheral Blood expression profiles of bone Morphogenetic Proteins tumornecrosis factorsuper family molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity and therapeutic responsiveness[J].J Rheumatol, 2010,37(2):246-256.
[75]De A.Wnt/Ca2+signaling pathway: a brief overview[J].Acta Biochim Biophys Sin,2011,43(10):745-756.
[76]Mezzacapppa C,Komiya Y,Habas R.Activation and function of small GTPases Rho,Rac,and Cdc42 during gastrulation[J].Methods Mole Biol, 2012,839: 119-131.
[77]Peyvndi F,Jayandharan G,Chandy M,et al.Genetic diagnosis of Hemophilia and other inherited bleeding disorders[J].Haemophilia, 2006,12:82-89.
[78]Su Y,wong W Y,Lai A,et al.long-term major joint outcomes in young adults with haemophilia:interim dada from the HGDSE[J].Haemophilia,2007,13:1-4.
[79]leissinger C A.Advances in the clinical management of inhibitors in hemophilia A and B[J].Semin Hematol,2016,53(1):20-27.
[80]Li X J,CHen Z P,Wu R H.Interpretation of Expert Guidance of ped atric hemophilia in China (2017)[J].Chinese Journal of Practical pediatrics Jan,2017,32(1):11-15.
[81]Tengborn L,Baudo F,huth-kuhne A,et al.Pregnancy-associated acquired hemophilia A:results from the european acquired Hemophilia(EACH2) Registry[J].Bjog,2012,119:1529-1537.
[82]Young J H,Wang J C,Gau J P,et al.Prenatal and molecular diagnosis of hemophilia B[J].American Journal of hematology,1996,52:243-247.
[83]White G C,Rosendaal F, Aledort L M,et al.Definitions in hemophilia:recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis[J].Thromb haemost,2001,85:560.
[84]Rodriguez N,Hoots W K.Advances in hemophilia:experimental aspects and therapy[J].Pediats Clin North Am,2008:357-376.
[85]Goedert J J,Eyster M E,Lederman M M,ea al.End-stage liver disease in persons with hemophilia and hemophilia and transfusion.associated infections[J].Blood,2002,100:1584-1589.
[86]Wang Z Y,Li J Z,Ruan C G,et al.Thrombosis & Hemostasis Basic Principles &Clinical Practice[J].Shanghai: Shanghai Scientific & Technical Publishers,2004:397-402.
[87]Valentino L A,Kempton C L,Kruse-Jarres R,et al.US guidelines for immune tolerance induction in Patients with haemophilia A and inhibitors [J].Haemophilia,2015,21(5):559-567.
[88]Gomez K,Klamroth R,Mahlangu J,et al.Key issues in inhibitor management in patients with hemophilia[J].Blood Transdus,2014,12(Suppl 1):319-329.
[89]Avest P C,Fischer K,Mancuso M E,et al.Risk stratification for inhibitor development at first treatemnt For severe hemophilia A:a tool for clinical practice[J].J Thromb Haemost,2008,6(12):2048-2054.
[90]Hoyer L W,Scandella D.Factor Ⅷ inhibitors:structure and function in autoantibody and hemophilia A patients[J].Semin Hematol,1994,31(2 Suppl 4):1-5.
[91]Lusher J M,Arkin S,Abildgaard C F,et al.Recombinant factor Ⅷ for the treatment of previously untreated patients with hemophilia A-safety,efficacy, and development of inhibitors.Kogenate Previously Untreated Patient Study Group [J].N Engl J Med,1993,328(7):453-459.
[92]Bray G L,Gomperts E D,Courter S,et al.A niulticenter study of recombinant factor Ⅷ (recombimated):safety,efficacy,and inhibitor risk in previously untreated patients with hemophilia A.The Recombinated Study Group [J].Blood,1994,83(9):2428-2435.
[93]Gouw S C,van der Bom J G,Ljung R,et al.Factor Ⅷ products and inhibitor development in severe hemophilia A [J].N Engl J Med,2013,368(3):231-239.
[94]Astermark J,Betntorp E,White G C,et al.The Malmo International Brother Study[MIBS]:further support for genetic predisposition to inhibitor development in hemophilia patients[J].Haemophilia,2001,7(3):267-272.
[95]Gouw S C,van der Bom J G,Marijke van den Berg H.Treatmentrelated risk factors of inhibitor development in previously untreated patents with hemophilia A:the CANAL cohort study[J].Blood,2007,109(11):4648-4654.
[96]Gouw S C,van den Berg H M,Fischer K,et al.Intensity of factor Ⅷ treatment and inhibitor development in children with severe hemophilia A:the RODIN study[J].Blood,2013,121(20):4046-4055.
[97]Auerswald G,Kurnik K,Aledort L M,et al.The EPIC study:a lesson to learn[J].Haemophilia,2015,21(5):622-628.
[98]Collins P W,Bjorkman S,Fischer K,et al.Factor Ⅷ requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A:influences of variance in pharmacokinetics and treatment regimens [J].J Thromb Haemost,2010,8(2):269-275.
[99]Valentino L A,Mamonov V,Hellmann A,et al.A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management[J].J Thromb Haemost,2012,10(3):359-367.
[100]Valentino L A.Considerations in individualizing prophylaxis in patients with haemophilia A[J].Haemophilia,2014,20(5):607-615.
[101]Barnes C.Importance of pharmacokinetics in the management of hemophilia [J].Pediatr Blood Cancer,2013,60 (Suppl 1):S27-29.
[102]Laffan M.New products for the treatment of haemophilia[J].Br J Haematol,2016,172(1):23-31.
[103]Kitazawa T,Igawa T,Sampei Z,et al.A bispecific antibody to factors IXa and X restores factor Ⅷ hemostatic activity in a hemophilia A model[J].Nat Med,2012,18(10):1570-1574.
[104]Alok S.Inflammation is key to hemophilic arthropathy [J].Blood, 2015,126(19):2175-2176.
[105]Valentino L A,Kempton C L,Kruse Jarres R,et al.US guidelines for immune tolerance induction in patients with haemophilia A and inhibitors[J].haemophilia,2015,21(5):559-567.
[106]Antun A,Monahan P E,Manco Johnson M J,et al.Inhibitor recurrence after immune tolerance induction:a multicenter retrospective cohort study[J].J Thromb Haemost,2015,13(11):1980-1988.
[107]High K A,Skinner M W.Cell phones and landlines:the impact of gene therapy on the cost and availability of treatment for hemophilia[J].Mol Ther,2011,19(10):1749-1750.
[108]Peyvandi F, Jayandharan G, Chandy M, et al.Genetic diagnosis of haemophilia and other inherited bleeding disorders[J].Haemophilia, 2006,12:82-89.
[109]Su Y,Wong W Y,Lail A,et al.Long-term major joint outcomes in young adults with haemophilia:interim data from the HGDS[J].Haemophilia, 2007,13:1-4。
[110]Leuer M,Oldenburg J,Lavergne J M,et al.Somatic mosaicism in hemophilia A:a fairly common event[J].Am J Hum Genet, 2001,69:75-87.
[111]Coppola A , Favaloro, Tufano A,et al.Acquired inhibitors of coagulation factors:part:Ⅰ-acquired hemophilia A[J].Semin Thromb Hemost,2012,38:433-446.
[112]Knoebl P,Marco P,Baudo F,et al.Demographic and clinical data in acquired haemophilia A:results from the European Acquired Hemophilia Registry (EACH2)[J].J Thromb Hemost, 2012, 10:622-631.
[113]Srivastava A,Brewer A K,Mauser-Bunschoten E P,et al.Guidelines for the management of hemophilia[J].Haemophilia, 2013, 19:e1-e47.
[114]Rodriguez N I,Hoots W K.Advances in hemophilia: experimental aspects and therapy[J].Pediatr Clin North Am, 2008,55:357-376.
[115]Goedert J J,Eyster M E, Lederman M M,et al.End-stage liver disease in persons with hemophilia and hemophilia and transfusion-associated infections[J].Blood,2002,100:1584-1589.
[116]Nathwani A C,Rosales C,Mclntosh J,et al.Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human KIX Pseudotyped with serotype 5 and 8 capsid proteins[J].Mol ther,2011,19:876-885.
[117]Allay J A, Sleep S, Long S, et al.Good manufacturing practice production of selfcomplementary serotype8 adeno-associated viral vector for a hemophilia B clinicaltrial[J].Hum Gene Ther,2011,22:595-604.
[118]Benntt and plum.Cecil Textbook of Medicine.zoth edition[M].Philadelphia:W.B.Saunders, 1996,6:37.
[119]Shen P S.Chinese medicine pharmacology and clinical application[M].Beijing:People's Medical Publishing House, 2006:75-236.
[120]Lin W T , Zhu P.Applied clinical immunology[M].Xi'an:Fourth Military Medical University Press,2003:526-542.
[121]Knoebl P,Marco P,Baudo F,et al.Demographic and clinical data in acquierd Hemophilia A:results from the European Acquired Haemophilia Registry (EACH2)[J].J Thromb Hemost,2012,10:622-631.
[122]Collins P,Baudo F,Knoebl F,et al.Immuunosuppression for acpuired hemophlia A:results from the European Acquierd Haemophilia Registry (EACH2)[J].Blood,2012,120:47-55.
[123]Baudo F,Collins P,huth-Kuhne A,et al.Management of bleeding in acquired hemophilia A:results from the European Acquired Haemophilia(EACH2) Registry[J].Blood,2012,120:39-46.
[124]Tengborn L,Baudo F,Huth-Kuhne A,et al.Pregnancy-associated acquired hemophilia A:results from the European Acquired Haemophilia(EACH2) Registry[J],Bjog,2012,119:1529-1537.
[125]Young J H,Wang J C,Gau J P,et al.Prenatal and molecular diagnosis of hemophilia B[J].American Journal of Hematology,1996,52:243-247.
[126]Sánchez-García J F,Gallardo D,Navarro J,et,al.A versatile strategy for preimplantation genetic diagnosis of haemophilia A based on F8-gene sequencing[J].Thrombosis and Haemostasis, 2006,96:839-845.
[127]White G C,Rosendaal F,Aledort L M,et al.Definitions in hemophilia: recommendation of the scientific subcommittee on factor Ⅷ and factor Ⅸ of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis[J].Thromb Haemost, 2001,85:560.
[128]LIU Shan-Xi,LIU Yi-Guo,LI Fei,et al.Clinical Study of Combination of Chinese Medicine and Western Medicine in Treatment of 500 Patients with Hemophilia Hemorrhage[J].Cjitwm 2011, 31(7):888-891.
[129]S.X.Liu,P.B.Li,Y.G.Liu,et al.Five in one therapy for graded treatment of Haemophilic arthritis[J].Haemophilia, 2016,22:208-213.